Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
Journal of Clinical Oncology, 06/10/09
Kim GP et al. - In a trial to determine whether overall survival (OS) of fluorouracil (FU)-refractory pts was noninferior when treated with second-line infusional FU, leucovorin, and oxaliplatin (FOLFOX4; arm B) vs irinotecan (arm A), it was confirmed that in pts who experienced treatment failure with front-line FU therapy, OS does not significantly differ whether second-line therapy begins with irinotecan or FOLFOX4. FOLFOX4 produces higher response rates (RR) and longer time to progression (TTP). Both arms had notable OS in pts who experienced treatment failure with first-line FU therapy.
Methods- Pts who experienced treatment failure with 1 prior FU-based therapy and had not received prior irinotecan or oxaliplatin, either for metastatic disease or within 6 mos of adjuvant FU therapy, were randomly assigned to arm A (irinotecan 350 or 300 mg/m2 every 3 wks) or arm B (FOLFOX4).
- 491 pts were randomly assigned (arm A, n=245; arm B, n=246); 288 (59%) had experienced treatment failure with FU for metastatic colorectal cancer.
- 227 pts (46%) received protocol-mandated third-line therapy (arm A, 43%; arm B, 57%).
- Median survival was 13.8 mos for initial treatment with FOLFOX4 and 14.3 mos for irinotecan.
- RR (28% vs 15.5%) and TTP (6.2 vs 4.4 mos) were significantly superior with FOLFOX4.
- In the nonrandom subset of pts who crossed over, RR and TTP improvements with FOLFOX4 continued into third-line treatment.
- Irinotecan therapy was associated with more grade 3 nausea, vomiting, diarrhea, and febrile neutropenia; FOLFOX4 was associated with more neutropenia and paresthesias.
Related Articles
Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
Annals of Oncology, 11/06/09
Relevance Score: 68%
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
Annals of Oncology, 10/19/09
Relevance Score: 68%
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
Annals of Oncology, 10/19/09
Relevance Score: 67%
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors
Investigational New Drugs, 10/08/09
Relevance Score: 67%
Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
Journal of Cancer Research & Clinical Oncology, 10/01/09
Relevance Score: 67%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09
Taurolidine in the prevention and therapy of lung metastases
European Journal of Cardio-Thoracic Surgery, 12/18/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
Journal of Viral Hepatitis, 12/17/09
Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy
Langenbeck's Archives of Surgery, 12/17/09
The efficacy and safety of telaprevir ? a new protease inhibitor against hepatitis C virus
Expert Opinion on Investigational Drugs, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


